←
@BiVictriXTherapeutics170 posts
@BiVictriXTherapeutics avatar

@BiVictriXTherapeutics

@BiVictriX

Exploiting the Bi-Cygni technology, delivering a new class of biotherapeutics with superior selectivity. linkedin.com/company/bivictr…

◷ Joined May 2021▧ 83 Photos and videos
@BiVictriXTherapeutics avatar
@BiVictriXTherapeutics@BiVictriX·11 Jul 2025

These compelling results demonstrate the potential of BVX002 to deliver meaningful efficacy where other B7-H4-targeted ADCs fall short. To read more about this study, visit our website.

Post attachment
@BiVictriXTherapeutics avatar
@BiVictriXTherapeutics@BiVictriX·11 Jul 2025

In a mouse unresponsive to AstraZeneca’s B7H4-TOPOi-based ADC, AZD8205, a single dose of BVX002 was not only able to reverse the exponential growth of the tumour but also resulted in tumour regressions of >62% in just 14 days!

@BiVictriXTherapeutics avatar
@BiVictriXTherapeutics@BiVictriX·11 Jul 2025

🚀 Exciting news from BiVictriX! Our lead solid‑tumour ADC, BVX002, has delivered tumour growth inhibition and regressions in an AZD8205-resistant mouse 🎯 New data shows that a single dose of BVX002 reverses tumour growth in an AZD8205-resistant mouse 🌟

@BiVictriXTherapeutics avatar
@BiVictriXTherapeutics@BiVictriX·1 Jul 2025

✅ Our Bi-Cygni® platform breaks through expression thresholds that limit conventional ADCs. 🧬 Precision, potency, and consistent DAR4 from our site-specific conjugation tech. We’re setting a new bar in #ADC innovation.

@BiVictriXTherapeutics avatar
@BiVictriXTherapeutics@BiVictriX·1 Jul 2025

While competitor ADCs mainly offered disease control, BVX002 showed statistically significant tumor regressions — up to 84.7% at 5mg/kg (p<0.001). Monospecific ADCs struggle in heterogeneous tumors. Ours doesn’t.

@BiVictriXTherapeutics avatar
@BiVictriXTherapeutics@BiVictriX·1 Jul 2025

🚀 Preclinical win for #BiVictriX: Our bispecific ADC, BVX002, outperformed 2 B7H4-targeted competitors (Pfizer’s SGN-B7H4V* & AZ’s AZD8205*) in head-to-head studies. 📊 Tumor regressions across all doses tested. 👇 More on why this matters:

@BiVictriXTherapeutics avatar
@BiVictriXTherapeutics@BiVictriX·19 Jun 2025

🔬 At BiVictriX, we’re not confined to 1 ADC design philosophy. Our BVX002 programme employs an innovative “AND/OR”-gated bispecific ADC to tackle ovarian cancer's tumour heterogeneity. It’s about clinically relevant solutions, not just being different. #ADC #bispecific #oncology

Post attachment
@BiVictriXTherapeutics avatar
@BiVictriXTherapeutics@BiVictriX·24 Aug 2023

We're pleased to announce our lead asset, BVX001, has been granted a US patent! This is a big step on BiVictriX's journey, providing broad protection for our lead therapeutic asset at the antigen level. Find out more: bivictrix.com/news/us-patent… #bloodcancer #AML #ADC #biotech

@BiVictriXTherapeutics avatar
@BiVictriXTherapeutics@BiVictriX·28 Jul 2023

Discover how our clinical lead candidate, BVX001, addresses some of the shortcomings of current antibody drug conjugate (ADC) treatments for acute myeloid leukaemia in this in-depth article in @Labiotech_eu labiotech.eu/in-depth/bivict… #ADC #AML #pipeline #biotech